Bivalirudin Trifluoroacetate

본문 바로가기


Home > Product > Bivalirudin Trifluoroacetate
Product
Bivalirudin Trifluoroacetate
Posting date : Sep 14, 2016
Membership
Free Member Scince Sep 14, 2016
FOB Price
Negotiable
Min. Order Quantity
5 grams
Supply Abillity
200 Kilograms/Month
Port
ShenZhen , ShangHai, HongKong
Payment Terms
Western Union, MoneyGram, T/T
Package
well package
Keyword :
Category
Contact
Alan
          0 likes     
Product Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
yuancheng
HS-CODE
2801-10
Package & Delivery Lead Time
Package
well package
Delivery Lead Time
within 3 days after payment
Detailed Description
Product Name    Bivalirudin Trifluoroacetate Sequence     D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OHCas No.     128270-60-0Molecular Formula     C98H138N24O33Molecular Weight     2180.33Purity (HPLC)    98.0%min.Appearance?    White PowderSingle Impurity (HPLC)?    1.0%maxAmino Acid Composition?    ±10% of theoreticalPeptide Content (N%)    ≥80.0% Water Content (Karl Fischer)?    ≤8.0%TrifluoroAcetate Content(HPIC)    ≤12.0%MS (ESI)    ConsistentMass Balance?    95.0~105.0%
2. Description:Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials.
3. Application:Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2024 ECROBOT.COM. All rights reserved.
Top